Broad-spectrum antiviral brincidofovir inhibits Epstein-Barr virus and related gammaherpesvirus in human and nonhuman primate cells
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci195764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Abaigeal Donaldson und 15 weiteren Autor:innen. Beteiligte Einrichtung: Viral Immunology Section, National Institute of Neurological Disorders and Stroke (NINDS) and. Hauptthemen laut MEDLINE: Antiviral Agents, Herpesvirus 4, Human, Cytosine, Organophosphonates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIH NINDS, SymBio Pharmaceuticals Limited, Tokyo, Japan.
Abstract (Originalsprache)
Epstein-Barr virus (EBV) is of growing interest for its potential role in neurodegenerative diseases such as multiple sclerosis (MS) and its possible utility as a therapeutic target in herpesvirus-associated chronic diseases. The effects of brincidofovir (BCV) on EBV reactivation were evaluated in vitro using EBV-infected spontaneous lymphoblastoid cell lines (SLCLs) and peripheral blood mononuclear cells (PBMCs) derived from patients with MS and healthy controls. In addition, a B lymphoblastoid cell line and PBMCs from common marmosets ( Callithrix jacchus ) naturally infected with an EBV-related gammaherpesvirus (Callitrichine herpesvirus 3, CalHV-3) were used to measure BCV efficacy in a nonhuman primate model. BCV significantly inhibited gammaherpesvirus reactivation, with decreased lytic and latent viral transcript expression. These results suggest that BCV may be a useful antiviral for inhibiting EBV activity in patients with MS. Additionally, this work further validates the utility of CalHV-3 in marmosets as a translational model for the investigation of successful EBV-targeting therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viral Immunology Section, National Institute of Neurological Disorders and Stroke (NINDS) and.
- Translational Neuroradiology Section, NINDS, NIH, Bethesda, Maryland, USA.
- Department of General and Experimental Pathology, Medical University of Białystok, Białystok, Poland.
- Experimental Immunotherapeutics Unit and.
- Animal Health and Care Section, NINDS, NIH, Bethesda, Maryland, USA.
- SymBio Pharmaceuticals Limited, Tokyo, Japan.
Förderung
- NIH HHS
- NIH NINDS
- SymBio Pharmaceuticals Limited, Tokyo, Japan
Zitieren
APA
Donaldson, A., Druker, M. R., Monaco, M. C., Stack, E. H., Zimmerman, P., Lee, A., Bialuk, I., Frazier, W., Cortese, I., Narver, H., Hazama, M., Yoshida, F., Li, X., Krug, L. T., Piotrowski, S. L., & Jacobson, S. (2026). Broad-spectrum antiviral brincidofovir inhibits Epstein-Barr virus and related gammaherpesvirus in human and nonhuman primate cells. Journal of Clinical Investigation. https://doi.org/10.1172/jci195764
Vancouver
Donaldson A, Druker MR, Monaco MC, Stack EH, Zimmerman P, Lee A, et al. Broad-spectrum antiviral brincidofovir inhibits Epstein-Barr virus and related gammaherpesvirus in human and nonhuman primate cells. Journal of Clinical Investigation. 2026. doi:10.1172/jci195764
BibTeX
@article{Donaldson2026,
author = {Donaldson, Abaigeal and Druker, Madeleine R and Monaco, Maria Chiara and Stack, Emily H and Zimmerman, Paige and Lee, Amanda and Bialuk, Izabela and Frazier, William and Cortese, Irene and Narver, Heather and Hazama, Masatoshi and Yoshida, Fuminori and Li, Xiaofan and Krug, Laurie T and Piotrowski, Stacey L and Jacobson, Steven},
title = {Broad-spectrum antiviral brincidofovir inhibits Epstein-Barr virus and related gammaherpesvirus in human and nonhuman primate cells},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci195764}
}
EUVIMED